177 related articles for article (PubMed ID: 36289130)
21. The economic burden of low back pain in KwaZulu-Natal, South Africa: A prevalence-based cost-of-illness analysis from the healthcare provider's perspective.
Kahere M; Ngcamphalala C; Östensson E; Ginindza T
PLoS One; 2022; 17(10):e0263204. PubMed ID: 36227919
[TBL] [Abstract][Full Text] [Related]
22. Idiopathic Pulmonary Fibrosis: Utilization of Health Services and Out-Of-Pocket Health Expenditures in Greece.
Naoum P; Athanasakis K; Skroumpelos A; Kyriopoulos J
Value Health Reg Issues; 2020 Sep; 22():44-48. PubMed ID: 32777730
[TBL] [Abstract][Full Text] [Related]
23. Recent trends in pirfenidone and nintedanib use for idiopathic pulmonary fibrosis in Australia.
Cox IA; de Graaff B; Corte TJ; Glaspole I; Chambers DC; Moodley Y; Teoh A; Walters EH; Palmer AJ
Aust Health Rev; 2021 Dec; 45(6):718-727. PubMed ID: 34706811
[TBL] [Abstract][Full Text] [Related]
24. The economic implications of treating atherothrombotic disease in Australia, from the government perspective.
Ademi Z; Liew D; Hollingsworth B; Wolfe R; Steg GP; Bhatt DL; Reid CM;
Clin Ther; 2010 Jan; 32(1):119-32; discussion 106-7. PubMed ID: 20171418
[TBL] [Abstract][Full Text] [Related]
25. Impact of Idiopathic Pulmonary Fibrosis on Longitudinal Health-care Utilization in a Community-Based Cohort of Patients.
Farrand E; Iribarren C; Vittinghoff E; Levine-Hall T; Ley B; Minowada G; Collard HR
Chest; 2021 Jan; 159(1):219-227. PubMed ID: 32717266
[TBL] [Abstract][Full Text] [Related]
26. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.
Jo HE; Glaspole I; Grainge C; Goh N; Hopkins PM; Moodley Y; Reynolds PN; Chapman S; Walters EH; Zappala C; Allan H; Keir GJ; Hayen A; Cooper WA; Mahar AM; Ellis S; Macansh S; Corte TJ
Eur Respir J; 2017 Feb; 49(2):. PubMed ID: 28232409
[TBL] [Abstract][Full Text] [Related]
27. The Economic Burden of Bronchiectasis: A Systematic Review.
Roberts JM; Goyal V; Kularatna S; Chang AB; Kapur N; Chalmers JD; Goeminne PC; Hernandez F; Marchant JM; McPhail SM
Chest; 2023 Dec; 164(6):1396-1421. PubMed ID: 37423293
[TBL] [Abstract][Full Text] [Related]
28. Burden of illness in idiopathic pulmonary fibrosis.
Collard HR; Ward AJ; Lanes S; Cortney Hayflinger D; Rosenberg DM; Hunsche E
J Med Econ; 2012; 15(5):829-35. PubMed ID: 22455577
[TBL] [Abstract][Full Text] [Related]
29. The burden of idiopathic pulmonary fibrosis: an unmet public health need.
Lee AS; Mira-Avendano I; Ryu JH; Daniels CE
Respir Med; 2014 Jul; 108(7):955-67. PubMed ID: 24780718
[TBL] [Abstract][Full Text] [Related]
30. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.
Jo HE; Glaspole I; Moodley Y; Chapman S; Ellis S; Goh N; Hopkins P; Keir G; Mahar A; Cooper W; Reynolds P; Haydn Walters E; Zappala C; Grainge C; Allan H; Macansh S; Corte TJ
BMC Pulm Med; 2018 Jan; 18(1):19. PubMed ID: 29370786
[TBL] [Abstract][Full Text] [Related]
31. Cost of gastroenteritis in Australia: A healthcare perspective.
Barker SF; Zomer E; O'Toole J; Sinclair M; Gibney K; Liew D; Leder K
PLoS One; 2018; 13(4):e0195759. PubMed ID: 29649285
[TBL] [Abstract][Full Text] [Related]
32. Socio-Economic Burden of Myasthenia Gravis: A Cost-of-Illness Study in Bulgaria.
Ignatova V; Kostadinov K; Vassileva E; Muradyan N; Stefanov G; Iskrov G; Stefanov R
Front Public Health; 2022; 10():822909. PubMed ID: 35309194
[TBL] [Abstract][Full Text] [Related]
33. Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease.
Khor YH; Goh NSL; Wong AW; Johannson KA; Marcoux V; Fisher JH; Assayag D; Manganas H; Khalil N; Kolb M; Ryerson CJ;
Ann Am Thorac Soc; 2022 Jun; 19(6):962-970. PubMed ID: 35007498
[No Abstract] [Full Text] [Related]
34. The economic impact of obesity in Kuwait: a micro-costing study evaluating the burden of obesity-related comorbidities.
Al-Sabah S; ElShamy A; Jois S; Low K; Gras A; Gulnar EP
J Med Econ; 2023; 26(1):1368-1376. PubMed ID: 37853705
[TBL] [Abstract][Full Text] [Related]
35. The societal burden of haemophilia A. II - The cost of moderate and severe haemophilia A in Australia.
Brown LJ; La HA; Li J; Brunner M; Snoke M; Kerr AM
Haemophilia; 2020 Aug; 26 Suppl 5():11-20. PubMed ID: 32935398
[TBL] [Abstract][Full Text] [Related]
36. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.
Cruess AF; Zlateva G; Xu X; Soubrane G; Pauleikhoff D; Lotery A; Mones J; Buggage R; Schaefer C; Knight T; Goss TF
Pharmacoeconomics; 2008; 26(1):57-73. PubMed ID: 18088159
[TBL] [Abstract][Full Text] [Related]
37. The increasing economic burden of multiple sclerosis by disability severity in Australia in 2017: Results from updated and detailed data on types of costs.
Ahmad H; Campbell JA; van der Mei I; Taylor BV; Zhao T; Palmer AJ
Mult Scler Relat Disord; 2020 Sep; 44():102247. PubMed ID: 32554286
[TBL] [Abstract][Full Text] [Related]
38. What difference a decade? The costs of psychosis in Australia in 2000 and 2010: comparative results from the first and second Australian national surveys of psychosis.
Neil AL; Carr VJ; Mihalopoulos C; Mackinnon A; Lewin TJ; Morgan VA
Aust N Z J Psychiatry; 2014 Mar; 48(3):237-48. PubMed ID: 24220136
[TBL] [Abstract][Full Text] [Related]
39. The economic cost of sleep disorders.
Hillman DR; Murphy AS; Pezzullo L
Sleep; 2006 Mar; 29(3):299-305. PubMed ID: 16553015
[TBL] [Abstract][Full Text] [Related]
40. What are the health and socioeconomic impacts of allergic respiratory disease in Tasmania?
Borchers-Arriagada N; Jones PJ; Palmer AJ; Bereznicki B; Cooling N; Davies JM; Johnston FH
Aust Health Rev; 2021 Jun; 45(3):281-289. PubMed ID: 33789077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
